Zetia

Type: Product
Name: Zetia
First reported Aug 22 2014 - Updated Aug 22 2014 - 1 reports

A cause for celebration

Happy birthday to Al Roker, who makes even a rainy day forecast seem jolly. Happy birthday to Amy Adams, who enchanted audiences in movies as diverse as Drop Dead Gorgeous, The Fighter, and American Hustle. Happy birthday to the late Jacqueline Susann, ... [Published Lexology - Aug 22 2014]
First reported Aug 22 2014 - Updated Aug 22 2014 - 1 reports

Buy rating on Glenmark Pharma

Summary Glenmark announced discovery of its first bi-specific antibody, GBR 1302.Glenmark announced discovery of its first bi-specific antibody, GBR 1302. This bispecific molecule has been developed using Glenmark’s proprietary antibody engineering platform ... [Published Financial Express - Aug 22 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

A Cause for Celebration

Happy birthday to Al Roker, who makes even a rainy day forecast seem jolly.  Happy birthday to Amy Adams, who enchanted audiences in movies as diverse as Drop Dead Gorgeous , The Fighter , and American Hustle .  Happy birthday to the late Jacqueline ... [Published Drug and Device Law - Aug 20 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

AHA announces late-breaking clinical trials for annual Scientific Sessions

The American Heart Association has announced the line-up of late-breaking clinical trials slated for presentation at its annual Scientific Sessions in Chicago.According to a press release, the meeting will feature four late-breaking clinical trial sessions ... [Published Orthopedics Today - Aug 13 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

SUNY Oneonta chemistry professor's discovery earns patent

A local chemistry professor is the second SUNY Oneonta faculty member to receive a U.S. patent, according to a recent media release from the college.Dr. Jacqueline Bennett, an associate professor of chemistry and biochemistry at the State University College ... [Published New York Daily Star - Aug 13 2014]
First reported Aug 05 2014 - Updated Aug 05 2014 - 1 reports

Merck & Co posts net profit of $2,004 million in Q2

Merck & Co has registered strong growth in profits during the second quarter ended June 2014 despite lower sales. Its net profit increased by 121 per cent to $2,004 million from $906 million in the corresponding period of last year. However, its net sales ... [Published PharmaBiz - Aug 05 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

US stocks finish lower on Russia sanctions

New York - US stocks finished lower on Tuesday after the United States and European Union broadened sanctions on Russia, overshadowing US economic data and earnings reports.The Dow Jones Industrial Average dropped 70.48 points (0.42%) to 16 912.11.The ... [Published News24 - Jul 30 2014]
First reported Jul 29 2014 - Updated Jul 29 2014 - 1 reports

US stocks finish lower as US, EU sanction Russia

NEW YORK: US stocks on Tuesday (July 29) finished lower after the United States and European Union broadened sanctions on Russia, overshadowing US economic data and earnings reports.The Dow Jones Industrial Average dropped 70.48 points (0.42 pe rcent) ... [Published Channel NewsAsia - Jul 29 2014]
First reported Jul 29 2014 - Updated Jul 29 2014 - 1 reports

Merck net income jumps to $2bn

NEW YORK: A big one-time gain and a tax benefit helped drugmaker Merck & Co. more than double its second-quarter profit, raise the lower end of its profit forecast and easily top analysts’ expectations.The maker of popular Type 2 diabetes pill Januvia ... [Published Arab News - Jul 29 2014]
First reported Jul 29 2014 - Updated Jul 29 2014 - 3 reports

US stocks rise on Pfizer, Merck earnings (AFP)

AFP US stocks rise on Pfizer, Merck earningsNew York (AFP) - US stocks Tuesday moved higher in early trade, lifted by earnings from drug makers Pfizer and Merck that topped Wall Street estimates.About 35 minutes into trade, the Dow Jones Industrial Average ... [Published West Australian - Jul 29 2014]
First reported Jul 29 2014 - Updated Jul 29 2014 - 1 reports

Merck 2Q profit more than doubles

A big one-time gain and a tax benefit helped drugmaker Merck & Co. more than double its second-quarter profit, raise the lower end of its profit forecast and easily top analysts' expectations. The maker of popular Type 2 diabetes pill Januvia and ... [Published The Washington Times stories: News - Jul 29 2014]
First reported Jul 29 2014 - Updated Jul 29 2014 - 1 reports

Merck ups earnings guidance after Q2 results

07:25 ET | About: Merck & Co Inc. (MRK)Merck (NYSE:MRK) Q2 results: Total Revenues: $10,934M (-0.7%), Pharmaceutical: $9,087M (-2.4%), Animal Health: $872M (+2.5%), Consumer Care: $583M (+19.0%), Other: $392M (+9.2%); Gross Profit: $6,041M (-10.2%); R&D ... [Published Seeking Alpha - Jul 29 2014]

Quotes

"When I was first experimenting with the method, I missed what was happening because I was writing in my notebook," Bennett said. "To my surprise, the compound, which looks like gold glitter, formed after only a few minutes. Other methods require hours of boiling. This worked so well and so quickly. I tried it again and again to see if it was true. I thought, ‘This is fabulous.’"
"Because the ENHANCE trial was focused on carotid-intima media thickness, as opposed to a clinical outcome, the results were not expected to be"
"There's always economic blowback" from sanctions, he said. "Whenever trade is restrained in any way, that creates dislocations and distortions that are generally negative."
Sanford Bernstein analyst Tim Anderson has reportedly said in a research note that Merck "will likely have another flattish year in 2014 in terms of financial performance but then growth should return more consistently thereafter"

More Content

All (41) | News (32) | Reports (0) | Blogs (8) | Audio/Video (0) | Fact Sheets (1) | Press Releases (0)
sort by: Date | Relevance
A cause for celebration [Published Lexology - Aug 22 2014]
Buy rating on Glenmark Pharma [Published Financial Express - Aug 22 2014]
A Cause for Celebration [Published Drug and Device Law - Aug 20 2014]
AHA announces late-breaking clinical trials for... [Published Orthopedics Today - Aug 13 2014]
SUNY Oneonta chemistry professor's discovery ea... [Published New York Daily Star - Aug 13 2014]
Should You Be Taking a Statin? [Published US News & World Report - Aug 12 2014]
Ezetimibe initiations declined, discontinuation... [Published Orthopedics Today - Aug 11 2014]
Sanofi and Regeneron pay $67.5m to speed aliroc... [Published PMLive - Aug 06 2014]
Merck - Current Valuation Is Based On Future Pi... [Published Seeking Alpha - Aug 05 2014]
Merck & Co posts net profit of $2,004 million i... [Published PharmaBiz - Aug 05 2014]
Familial hypercholesterolemia guideline urges e... [Published Orthopedics Today - Aug 04 2014]
ENHANCE Study Had Impact on Ezetimibe New Users... [Published American Journal of Public Health - Aug 01 2014]
Alirocumab Safely Lowers LDL Cholesterol in Nin... [Published American Journal of Public Health - Jul 30 2014]
Positive Results Reported From Nine Phase III T... [Published PT Community - Jul 30 2014]
UPDATE 1-Sanofi, Regeneron cholesterol drug may... [Published Reuters - Jul 30 2014]
Sanofi Cholesterol Drug Meets Main Goal of 9 Tr... [Published Bloomberg - Jul 30 2014]
US stocks finish lower on Russia sanctions [Published News24 - Jul 30 2014]
Merck & Co sees Q2 profit rocket [Published Pharma Times - Jul 29 2014]
Merck net income jumps to $2bn [Published Arab News - Jul 29 2014]
US stocks finish lower as US, EU sanction Russia [Published Channel NewsAsia - Jul 29 2014]
Merck's (MRK) CEO Lynn Fuller on Q2 2014 Result... [Published Seeking Alpha - Jul 29 2014]
Merck's revenue drops 1% but still beats analys... [Published Pharma Letter - Jul 29 2014]
US stocks rise on Pfizer, Merck earnings (AFP) [Published West Australian - Jul 29 2014]
Fin24.com | US stocks rise on Pfizer, Merck ear... [Published Finance 24 - Jul 29 2014]
US stocks rise on Pfizer, Merck earnings [Published Trading Room - Jul 29 2014]
Merck 2Q profit more than doubles [Published The Washington Times stories: News - Jul 29 2014]
Merck ups earnings guidance after Q2 results [Published Seeking Alpha - Jul 29 2014]
Health Column: Statin drugs and high cholesterol [Published Glenwood Independent - Jul 28 2014]
Glenmark continues to struggle in US [Published Business Standard India - Jul 24 2014]
Why are doctors still prescribing Zetia? [Published KevinMD.com - Jul 10 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
A Cause for Celebration [Published Drug and Device Law - Aug 20 2014]
Happy birthday to Al Roker, who makes even a rainy day forecast seem jolly.  Happy birthday to Amy Adams, who enchanted audiences in movies as diverse as Drop Dead Gorgeous , The Fighter , and American Hustle .  Happy birthday to the late Jacqueline ...
Why are doctors still prescribing Zetia? [Published KevinMD.com - Jul 10 2014]
A health research company just released a list of the 100 top drugs in America according to sales. 29th on the list, with sales of over $1.8 billion, is the cholesterol lowering drug ezetimibe, brand name Zetia. Continue reading ... Your patients ...
There They Go Again - Merck Threatened Legal Ac... [Published Health Care Renewal - Jul 08 2014]
It seems that when confronted with unfavorable facts or opinions, Merck executives like to threaten legal action, rather than just argue their side of the case.  Last month we discussed how Merck officials used the US court system to try to prevent ...
Larry Husten writes [Published PharmaGossip - Jul 07 2014]
Merck Uses Legal Threats To Stifle Negative Advice About Zetia And Vytorin In Italy In response to repeated legal threats, a public health doctor in Italy has withdrawn advice to curtail use of a controversial drug. The drug, ezetimibe, is a key ingredient ...
Global Genomics Group ("G3") Appoints Harry "Ch... [Published PR Newswire: Health - May 06 2014]
RICHMOND, Va., May 6, 2014 /PRNewswire/ -- Global Genomics Group (G3), a life sciences company investigating biological networks that lead to the development of disease to identify novel diagnostic biomarkers and therapeutic targets, today announced the ...
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.